The UK's Pound Sterling (GBP) plummeted yesterday, recording one of its worst days of trading across the past three decades. Moreover,…
McAlinden Research PartnersSeptember 27, 2022
The glow of Zoom and other stocks that boomed on the "work from home" trade has faded in 2022 amid a…
McAlinden Research PartnersAugust 23, 2022
M&A activity is picking up among pharmaceutical firms with large cash balances. Pfizer and Amgen have each closed a multi-billion…
McAlinden Research PartnersAugust 9, 2022
A relentless, yearlong rise in the relative value of the US Dollar recently sent the greenback to multi-decade highs versus…
McAlinden Research PartnersAugust 8, 2022
After several downward revisions to Bitcoin's (BTC) mining difficulty, computing power provided to the network appears to be rising again.…
McAlinden Research PartnersAugust 8, 2022
The number of cyberattacks are on the rise, but the average cost of each attack is increasing even faster. Billions of…
McAlinden Research PartnersJuly 22, 2022
US banks' second quarter results helped to map out an uncertain future for the financial sector. Trading revenues rose but…
McAlinden Research PartnersJuly 19, 2022
Psychedelic medicine, focused on alternative mental health therapies that utilize drugs like LSD, MDMA and psilocybin, is becoming increasingly popular…
McAlinden Research PartnersJuly 18, 2022
Last year marked one of the least active years for biopharma merger and acquisition (M&A) activity in a decade. The first…
McAlinden Research PartnersJuly 14, 2022
